According to the results of a new study, a woman's risk of breast cancer is small with limited use of hormone replacement therapy (HRT). The research shows there is a safe period for combined estrogen and progesterone (E+P) hormone replacement therapy of two to three years after menopause. Breast cancer risk drops dramatically when HRT is discontinued.
The study comes from the Department of Epidemiology and Surveillance Research at the American Cancer Society, in Atlanta, Georgia; published January 20 in the journal Cancer. The authors say, "In combination, these findings suggest a window of 2 to 3 years for the risks of E+P [estrogen and progesterone] to become apparent after initial use and to attenuate following cessation." Read more...
According to the results of a new study, a woman's risk of breast cancer is small with limited use of hormone replacement therapy (HRT). The research shows there is a safe period for combined estrogen and progesterone (E+P) hormone replacement therapy of two to three years after menopause. Breast cancer risk drops dramatically when HRT is discontinued.
The study comes from the Department of Epidemiology and Surveillance Research at the American Cancer Society, in Atlanta, Georgia; published January 20 in the journal Cancer. The authors say, "In combination, these findings suggest a window of 2 to 3 years for the risks of E+P [estrogen and progesterone] to become apparent after initial use and to attenuate following cessation." Read more...